Drug Briefing: Lenacapavir
Query Drug:LenacapavirQuery Time:2024-06-24 11:06:36*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest

Lenacapavir: Market Analysis of the First-in-Class Capsid Inhibitor
In August 2022, Gilead announced that the European Commission (EC) has granted marketing authorization for Sunlenca (Lenacapavir), an innovative treatment for adults with multi-drug resistant HIV infection. The treatment works in combination with other antiretroviral(s) when it isn't

HIV, a Typical Retrovirus Life Cycle
HIV, or human immunodeficiency virus, is a retrovirus that infects and destroys the immune system's CD4+ T cells, leading to acquired immunodeficiency syndrome (AIDS). But how does this tiny virus manage to invade cells and cause so much damage? Here's an overview.
